Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.25%||162.64||0.7%||$1229.36m|
|MRK||Merck & Co., Inc.||0.18%||77.61||0.7%||$782.74m|
|BMY||Bristol-Myers Squibb Co.||0.44%||65.75||1.0%||$703.61m|
|LLY||Eli Lilly & Co.||0.25%||189.73||1.1%||$539.14m|
|RPRX||Royalty Pharma Plc||-0.24%||41.77||0.2%||$91.76m|
|NVO||Novo Nordisk A/S||0.75%||72.71||0.1%||$62.90m|
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.